Cidara Therapeutics Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cidara Therapeutics Inc 's ROA in the third quarter of 2025?
Cidara Therapeutics Inc recorded a cumulative net loss of $-148 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -40.81%.

However, within the Healthcare sector 511 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 3913, from total ROA ranking in the second quarter of 2025 at 4144.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Total Assets Change	223.25 %	211.42 %	277.61 %	242.75 %	165.96 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-148	-156	-141	-122	-116
Return On Assets (TTM)	-40.81 %	-57.03 %	-76.74 %	-82.3 %	-104.1 %
CDTX's Total Ranking	# 3913	# 4144	# 4389	# 5099	# 4643
Total Assets (TTM) in million	518	533	190	213	160
Seq. Total Assets Change	-2.78 %	180.3 %	-10.81 %	33.01 %	-6.34 %
Seq. Net Income Change	-	-	-	-	-

CDTX's 5 Years Annual ROA >> Back to CDTX Management Effectiveness >> Compare CDTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 67
Sector	# 512
Overall	# 3867

Return On Assets Statistics
High	Average	Low
-10.81 %	-65.77 %	-129.41 %
(Jun 30 2023)		(Jun 30 2024)

Financial Statements
Cidara Therapeutics Inc 's Assets	$ 518 million	CDTX's Balance sheet
Cidara Therapeutics Inc 's Income	$ -83 million	Quarterly CDTX's Income Statement
CDTX's Income by Division		See CDTX's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	226.02 %	41.23 %	-37.37 %	22.39 %	-12.4 %
Total Assets in million	213	65	46	74	60
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-170	-23	-30	-42	-72
Annual Return On Assets	-79.63 %	-35.06 %	-64.34 %	-57.42 %	-119.34 %

CDTX's 5 Years Annual ROA >> Back to CDTX Management Effectiveness >> Compare CDTX ROA to its Competitors

More Return On Assets Ratios
CDTX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CDTX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CDTX's Competitors
Subscribers only: Roa for Cidara Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CDTX's Customers

You may also want to know
CDTX's Roi	CDTX's Inventory Turnover Ratio	CDTX's Growth Rates	CDTX's Dividend Comparisons
	CDTX's Profitability Ratios	CDTX's Asset Turnover Ratio	CDTX's Dividend Growth
CDTX's Roe	CDTX's Valuation Ratios	CDTX's Financial Strength Ratios	CDTX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T17:04:55+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.